Overview of mercury radionuclides and nuclear model calculations of<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline"><mml:msup><mml:mrow /><mml:mn>195</mml:mn></mml:msup></mml:math>Hg<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline"><mml:msup><mml:mrow /><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>g</mml:mi></mml:mrow></mml:msup></mml:math>and<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline"><mml:msup><mml:mrow /><mml:mn>197<

Sadeghi, Mahdi; Bakhtiari, Mahdi; Bakht, Martin; Anjomrouz, Marzieh; Mokhtari, L.

doi:10.1103/physrevc.85.034605

Cited by 12 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently there has been some interest in reviving mercury for use as a theragnostic radionuclide. 301,302 Walther et al recently reported the production of high-purity 197m /197 Hg by irradiation of a gold foil with a 10 MeV proton beam. 302 This route is less expensive than previous approaches that used enriched Hg targets because 197 Au is 100% abundant.…”

Section: Radionuclide Productionmentioning

confidence: 99%

Radioactive Transition Metals for Imaging and Therapy

2018

View full text Add to dashboard Cite

Nuclear medicine is composed of two complementary areas, imaging and therapy. Positron emission tomography (PET) and single-photon imaging, including single-photon emission computed tomography (SPECT), comprise the imaging component of nuclear medicine. These areas are distinct in that they exploit different nuclear decay processes and also different imaging technologies. In PET, images are created from the 511 keV photons produced when the positron emitted by a radionuclide encounters an electron and is annihilated. In contrast, in single-photon imaging, images are created from the γ rays (and occasionally X-rays) directly emitted by the nucleus. Therapeutic nuclear medicine uses particulate radiation such as Auger or conversion electrons or β − or α particles. All three of these technologies are linked by the requirement that the radionuclide must be attached to a suitable vector that can deliver it to its target. It is imperative that the radionuclide remain attached to the vector before it is delivered to its target as well as after it reaches its target or else the resulting image (or therapeutic outcome) will not reflect the biological process of interest. Radiochemistry is at the core of this process, and radiometals offer radiopharmaceutical chemists a tremendous range of options with which to accomplish these goals. They also offer a wide range of options in terms of radionuclide half-lives and emission properties, providing the ability to carefully match the decay properties with the desired outcome. This Review provides an overview of some of the ways this can be accomplished as well as several historical examples of some of the limitations of earlier metalloradiopharmaceuticals and the ways that new technologies, primarily related to radionuclide production, have provided solutions to these problems.

show abstract

Section: Radionuclide Productionmentioning

confidence: 99%

Radioactive Transition Metals for Imaging and Therapy

2018

View full text Add to dashboard Cite

show abstract

“…Listed are radioisotopes generated in reactions with cross sections above 10 mb and with halflife of at least 5 h. The cross section values are given for pure isotopes Substrate Main product Reaction Energy threshold (MeV) Cross section (1) (mb) Product decay [7] Product half-life [7] Energy of principal radiation emitted by the product (keV0 (probability) [7,195] Au 197 Hg [17, 31, 32] 197 Au(p,n) ca. 1-2 [85,196] c a .5 0 -80 [197] E C (4) 61.14 days γ: 191 (1%); 77 (18%) e −(2) : 57 (136%) X-rays: max. ca.…”

Section: Target Electrodepositionmentioning

confidence: 99%

Electrochemical deposition of nickel targets from aqueous electrolytes for medical radioisotope production in accelerators: a review

Mieszkowska

Grdeń

2021

J Solid State Electrochem

View full text Add to dashboard Cite

This paper reviews reported methods of the electrochemical deposition of nickel layers which are used as target materials for accelerator production of medical radioisotopes. The review focuses on the electrodeposition carried out from aqueous electrolytes. It describes the main challenges related to the preparation of suitable Ni target layers, such as work with limited amounts of expensive isotopically enriched nickel; electrodeposition of sufficiently thick, smooth and free of cracks layers; and recovery of unreacted Ni isotopes from the irradiated targets and from used electrolytic baths.

show abstract